Advertisement

Chinese Journal of Integrative Medicine

, Volume 16, Issue 2, pp 131–137 | Cite as

Effect of Tanreqing Injection (痰热清注射液) on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei (肺)

  • Wen Li (李 文)
  • Bing Mao (毛 兵)Email author
  • Gang Wang (王 刚)
  • Lei Wang (王 蕾)
  • Jing Chang (常 静)
  • Ying Zhang (张 颖)
  • Mei-hua Wan (万美华)
  • Jia Guo (郭 佳)
  • Yu-qiong Zheng (郑玉琼)
Original Article

Abstract

Objective

To explore the effect of Tanreqing Injection (痰热清注射液, TRQI) on the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with Chinese medicine syndrome of retention of phlegm and heat in Fei (痰热阻肺证, RPHF).

Methods

In a prospective randomized controlled clinical trial, 90 patients with AECOPD of RPHF syndrome were randomly assigned to 3 groups, TRQI and controls A and B, each with 30 cases. The TRQI group was administered with the intravenous injections of 20 mL TRQI once a day and conventional Western medicine treatment. Control group A was administered with the intravenous injection of 15 mg ambroxol hydrochloride twice a day and conventional Western medicine treatment, and control group B was administered with conventional Western medicine treatment only. The treatments were administered for 10 days. Chinese medical symptoms and signs were scored, and plasma concentrations of interleukin (IL)-8 and neutrophil elastase (NE) were recorded.

Results

(1) The Chinese medical symptoms (cough, sputum amount, expectoration, dyspnea and fever) and signs (tongue and pulse) improved significantly in the TRQI group (P<0.05 or P<0.01), and improvements in cough, sputum amount and expectoration were better in the TRQI group than control group B (P<0.05); there was no significant difference between the TRQI group and control group A (P>0.05). The sign of tongue was also improved significantly in the TRQI group (P<0.05). (2) The overall effects in the TRQI group and control group A were significantly better than in control group B (P<0.05), with no significant differences between the TRQI group and control group A (P>0.05). There was no significant difference in the total effective rate among the three groups (P>0.05). (3) After treatment, the plasma concentrations of IL-8 and NE decreased in the TRQI group and control group A (P<0.05), and the concentration of IL-8 in control group B decreased (P<0.05). The difference in IL-8 was greater in the TRQI group than in control group A and B before and after treatment, and the change in NE was greater in control group A than in the TRQI group and control group B, but there was no statistical significance among the three groups with regards to the change in IL-8 or NE (P>0.05).

Conclusion

TRQI could improved the Chinese medical signs and symptoms in the patients with AECOPD, possibly because of the decreasing plasma levels of IL-8 and NE which could improve response to airway inflammation and mucus hypersecretion.

Keywords

Tanreqing Injection acute exacerbation of chronic obstructive pulmonary disease retention of phlegm and heat in Fei randomized controlled trial interleukin-8 neutrophil elastase 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Global strategy for the diagonsis, management, and prevention of chronic obstrutive lung disease. Updated 2008. http//www.goldcopd.org
  2. 2.
    Bao TY. A review on treating COPD in Chinese medicine. Chin J Pract Mod Med (Chin) 2008;21:397–399.Google Scholar
  3. 3.
    Peng B, Zhang NH, Ji HY, Li GL, Ren W, Chen W. Effect of Tanreqing on chronic obstructive pulmonary disease (pulmonary retention of phlegm pyrexia). J Emerg Tradit Chin Med (Chin) 2007;16:1456–1457.Google Scholar
  4. 4.
    Zhang HJ, Wei ZL. Effect of Tanreqing on chronic obstructive pulmonary disease combined with infection. Med Forum Basic (Chin) 2006;10:1150–1150.Google Scholar
  5. 5.
    Chinese Sociey of Respiratory Diseases. Diagnosis and treatment guidance of chronic obstructive pulmonary disease. Chin Tuberc Respir Dis (Chin) 2002;25:453–460.Google Scholar
  6. 6.
    Zheng XY. Guiding principle of clinical research on new drugs of Chinese medicine. Bejing: China Medico-Pharmaceutical Sciences and Technology Publishing House; 2002:54–58.Google Scholar
  7. 7.
    Wang K, Feng YL, Wen FQ, Chen XR, Ou XM, Xu D, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease. Acta Pharmacol Sin 2007;828:1166–1174.CrossRefGoogle Scholar
  8. 8.
    Sitompul PA, Sutoyo DK, Antariksa B, Kadarsih R. Contribution lower airway bacterial colonization to persistent airway lumen inflammation and progression of airway disease in chronic obstructive pulmonary disease. Respirology (Suppl) 2008;13:102–110.Google Scholar
  9. 9.
    Devalia JL, Mills PR, Sapsford RJ, Seemungal T, Davies RJ. The effect of exposure to diesel exhaust particles (DEP) on IL-8 release from bronchial epithelial cells cultured from biopsies of non-smokers, smokers with normal pulmonary function and patients with chronic obstructive pulmonary disease (COPD). Allergy 1998;53:64.CrossRefGoogle Scholar
  10. 10.
    Sullivan A, Gompertz S, Bayley D, Stockley R. Sputum eosinophilia in chronic obstructive pulmonary disease (COPD): relationship with interleukin-8 (IL-8) in spontaneous and induced sputum sol. Thorax (Suppl) 2001;56:iii80–iii81.Google Scholar
  11. 11.
    Caramori G, Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 2003;16:247–277.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004;3:147–159.CrossRefPubMedGoogle Scholar
  13. 13.
    Currie GP, Butler CA, Anderson WJ, Skinner C. Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease:a new approach to oral treatment. Br J Clin Pharmacol 2008;65:803–810.CrossRefPubMedGoogle Scholar
  14. 14.
    Cianchetti S, Bacci E, Bartoli ML, Ruocco L, Pavia T, Dente FL, et al. Can hypertonic saline inhalation influence preformed chemokine and mediator release in induced sputum of chronic obstructive pulmonary disease patients?Comparison with isotonic saline. Clin Exp Allergy 2007;37:1819–1826.CrossRefPubMedGoogle Scholar
  15. 15.
    Celed’on JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004;13:1649–1656.CrossRefGoogle Scholar
  16. 16.
    Cai BQ, Zhu YJ, Xu L, Zhang H, Guo ZJ, Ma Y, et al. Clinical analysis of Huayu Kechuan tabletse (814) in patients with chronic obstructive pulmonary disease(312 cases). Bull Med Res (Chin) 2002;4(31):14–18.Google Scholar
  17. 17.
    Wang S, Zhang NZ, Ji HY, Li ZG. Yifei Jianpi Chinese medicine on airway inflammation of chronic obstructive pulmonary disease. Chin J Integr Tradit Med (Chin) 2002;22:462.Google Scholar
  18. 18.
    Zhang LL, Li Z, Xu XY, Li YM. Pharmacodynamic study of Tanreqing capsule. Chin J Exp Tradit Med Form (Chin) 2004; 10(3):37–40.Google Scholar
  19. 19.
    Gao YM, Wang ZS. Preliminary evaluation of clinical pharmacy of Tanreqing injection. Capital Med (Chin) 2004;11(12):44–46.Google Scholar
  20. 20.
    Huang B, Huang QX, Lu DS, Xie CM. Clinical research of Tanreqing Injection on acute exacerbation of chronic obstructive pulmonary disease. J Emerg Tradit Chin Med (Chin) 2006:5:464–466.Google Scholar
  21. 21.
    Xu CQ. Effect of Tanreqing Injection on cytokines and pulmonary function in patients with COPD. Pract Gen Med (Chin) 2006;4:401–402.Google Scholar
  22. 22.
    Zhang Y, Li TQ, Wang G, Chang J, Mao B, Wang L, et al. Randomized controlled trial of Tanreqing Injection in treatment of acute exacerbation of chronic obstructive pulmonary disease (syndrome of retention of phlegm-heat in the lung). Chin J Evid-Based Med (Chin) 2004;4:300–306.Google Scholar
  23. 23.
    Zhu YQ. The effect of ambroxola against airway inflammation of patients with chronic obstructive pulmonary disease. Hainan Med (Chin) 2006;12(17):6–7.Google Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Wen Li (李 文)
    • 1
    • 2
  • Bing Mao (毛 兵)
    • 1
    Email author
  • Gang Wang (王 刚)
    • 1
  • Lei Wang (王 蕾)
    • 1
  • Jing Chang (常 静)
    • 1
  • Ying Zhang (张 颖)
    • 1
  • Mei-hua Wan (万美华)
    • 1
  • Jia Guo (郭 佳)
    • 1
  • Yu-qiong Zheng (郑玉琼)
    • 2
  1. 1.Department of Integrated Chinese and Western Medicine, West China HospitalSichuan UniversityChengduChina
  2. 2.Department of Respiratory Medicinethe First People’s Hospital of Chengdu CityChengduChina

Personalised recommendations